303 related articles for article (PubMed ID: 19474412)
1. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy.
Cysique LA; Vaida F; Letendre S; Gibson S; Cherner M; Woods SP; McCutchan JA; Heaton RK; Ellis RJ
Neurology; 2009 Aug; 73(5):342-8. PubMed ID: 19474412
[TBL] [Abstract][Full Text] [Related]
2. HIV-associated brain dysfunction in the era of HAART: reasons for hope, but continued concern.
Cohen RA; Gongvatana A
Neurology; 2009 Aug; 73(5):338-9. PubMed ID: 19553591
[No Abstract] [Full Text] [Related]
3. Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda.
Sacktor N; Nakasujja N; Skolasky RL; Robertson K; Musisi S; Ronald A; Katabira E; Clifford DB
Neurology; 2009 Jan; 72(2):165-70. PubMed ID: 19139369
[TBL] [Abstract][Full Text] [Related]
4. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).
Ndhlovu LC; Umaki T; Chew GM; Chow DC; Agsalda M; Kallianpur KJ; Paul R; Zhang G; Ho E; Hanks N; Nakamoto B; Shiramizu BT; Shikuma CM
J Neurovirol; 2014 Dec; 20(6):571-82. PubMed ID: 25227930
[TBL] [Abstract][Full Text] [Related]
5. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.
Ellis RJ; Badiee J; Vaida F; Letendre S; Heaton RK; Clifford D; Collier AC; Gelman B; McArthur J; Morgello S; McCutchan JA; Grant I;
AIDS; 2011 Sep; 25(14):1747-51. PubMed ID: 21750419
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.
Robertson KR; Su Z; Margolis DM; Krambrink A; Havlir DV; Evans S; Skiest DJ;
Neurology; 2010 Apr; 74(16):1260-6. PubMed ID: 20237308
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.
Cysique LA; Brew BJ
J Neurovirol; 2011 Apr; 17(2):176-83. PubMed ID: 21416169
[TBL] [Abstract][Full Text] [Related]
9. Factors related to HIV-associated neurocognitive impairment differ with age.
Fogel GB; Lamers SL; Levine AJ; Valdes-Sueiras M; McGrath MS; Shapshak P; Singer EJ
J Neurovirol; 2015 Feb; 21(1):56-65. PubMed ID: 25404233
[TBL] [Abstract][Full Text] [Related]
10. Dementia and neurocognitive disorders due to HIV-1 infection.
Ances BM; Ellis RJ
Semin Neurol; 2007 Feb; 27(1):86-92. PubMed ID: 17226745
[TBL] [Abstract][Full Text] [Related]
11. Motor function and human immunodeficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort.
Robinson-Papp J; Byrd D; Mindt MR; Oden NL; Simpson DM; Morgello S;
Arch Neurol; 2008 Aug; 65(8):1096-101. PubMed ID: 18695060
[TBL] [Abstract][Full Text] [Related]
12. Empiric neurocognitive performance profile discovery and interpretation in HIV infection.
Gomez D; Power C; Gill MJ; Koenig N; Vega R; Fujiwara E
J Neurovirol; 2019 Feb; 25(1):72-84. PubMed ID: 30519968
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment.
Nakasujja N; Miyahara S; Evans S; Lee A; Musisi S; Katabira E; Robertson K; Ronald A; Clifford DB; Sacktor N
Neurology; 2013 Jan; 80(2):196-202. PubMed ID: 23269596
[TBL] [Abstract][Full Text] [Related]
14. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.
Heaton RK; Clifford DB; Franklin DR; Woods SP; Ake C; Vaida F; Ellis RJ; Letendre SL; Marcotte TD; Atkinson JH; Rivera-Mindt M; Vigil OR; Taylor MJ; Collier AC; Marra CM; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Abramson I; Gamst A; Fennema-Notestine C; Jernigan TL; Wong J; Grant I;
Neurology; 2010 Dec; 75(23):2087-96. PubMed ID: 21135382
[TBL] [Abstract][Full Text] [Related]
15. Association of Brain Structure Changes and Cognitive Function With Combination Antiretroviral Therapy in HIV-Positive Individuals.
Sanford R; Fellows LK; Ances BM; Collins DL
JAMA Neurol; 2018 Jan; 75(1):72-79. PubMed ID: 29131878
[TBL] [Abstract][Full Text] [Related]
16. CSF penetration by antiretroviral drugs.
Eisfeld C; Reichelt D; Evers S; Husstedt I
CNS Drugs; 2013 Jan; 27(1):31-55. PubMed ID: 23160938
[TBL] [Abstract][Full Text] [Related]
17. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
Heseltine PN; Goodkin K; Atkinson JH; Vitiello B; Rochon J; Heaton RK; Eaton EM; Wilkie FL; Sobel E; Brown SJ; Feaster D; Schneider L; Goldschmidts WL; Stover ES
Arch Neurol; 1998 Jan; 55(1):41-51. PubMed ID: 9443710
[TBL] [Abstract][Full Text] [Related]
18. Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.
Winston A; Stöhr W; Antinori A; Amieva H; Perré P; De Wit S; Reynes J; Gompels M; dʼArminio Monforte A; Gatell JM; Grarup J; Pozniak A; Babiker A; Raffi F; Richert L;
J Acquir Immune Defic Syndr; 2017 Feb; 74(2):185-192. PubMed ID: 27749603
[TBL] [Abstract][Full Text] [Related]
19. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
Vassallo M; Fabre R; Durant J; Lebrun-Frenay C; Joly H; Ticchioni M; DeSalvador F; Harvey-Langton A; Dunais B; Laffon M; Cottalorda J; Dellamonica P; Pradier C
J Neurovirol; 2017 Apr; 23(2):216-225. PubMed ID: 27815816
[TBL] [Abstract][Full Text] [Related]
20. HIV-associated neurocognitive disorders (HAND).
Elbirt D; Mahlab-Guri K; Bezalel-Rosenberg S; Gill H; Attali M; Asher I
Isr Med Assoc J; 2015 Jan; 17(1):54-9. PubMed ID: 25739180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
